Advertisement
Australia markets closed
  • ALL ORDS

    7,862.30
    -147.10 (-1.84%)
     
  • AUD/USD

    0.6404
    -0.0041 (-0.64%)
     
  • ASX 200

    7,612.50
    -140.00 (-1.81%)
     
  • OIL

    85.18
    -0.23 (-0.27%)
     
  • GOLD

    2,388.20
    +5.20 (+0.22%)
     
  • Bitcoin AUD

    97,695.31
    -5,818.54 (-5.62%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

1 Small-Cap Stock That Could Soar in 2023

1 Small-Cap Stock That Could Soar in 2023

Last year was an important one for Bluebird Bio (NASDAQ: BLUE) as the biotech company earned two key regulatory approvals in the U.S. Despite these wins, the market has hardly rewarded the gene-editing specialist; its shares are down 39% in the past year, and Bluebird's market capitalization is currently just $323 million. The company's newly approved therapies are Zynteglo, which targets transfusion-dependent beta-thalassemia (TDT, a rare blood disorder), and Skysona, a medicine for cerebral adrenoleukodystrophy (CALD, a progressive, pediatric, and fatal neurodegenerative disease). The issue here is whether third-party payers will agree to cover these medicines.